Skip to Content
Søk Menu

EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

The gut microbiome in patients with chronic lymphocytic leukemia

/ Carsten Utoft Niemann / Tereza Faitova
KLL
Tereza Faitova

Gut microbiome dysbiosis could be implicated in the pathogenesis of CLL

/ Tereza Faitova
EHA22KLL Play the Video 5:04
Matthew S. Davids

ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

/ Matthew S. Davids
ASH21KLL Play the Video 2:37
Paolo Ghia

How can we use Minimal Residual Disease in the treatment of CLL?

/ Paolo Ghia
ASH21KLL Play the Video 2:03

Forskellige mål for behandling af CLL

/ Carsten Utoft Niemann
KLL Play the Video 9:56
Talha Munir

MRD analysis in 1L Treatment of CLL in Elderly or Unfit patients

/ Talha Munir
ASH21KLL Play the Video 6:06
Matthew S. Davids

Retreatment with venetoclax + anti-CD20 monoclonal antibody for patients with relapsed/refractory CLL

/ Matthew S. Davids
ASH21KLL Play the Video 2:37
Sigrid Skånland

MRD ved behandling av KLL – en oppdatering fra ASH

/ Sigrid S. Skånland
ASH21KLL Play the Video 5:15
Florence Ajchenbaum-Cymbalista

Humoral Response to COVID-19 Vaccines in patients with CLL

/ Florence Ajchenbaum-Cymbalista
ASH21COVID-19KLL Play the Video 3:34
Back to top